Macrophage activation-like syndrome: A distinct entity leading to early death in sepsis

Frontiers in Immunology

Volumn 10, Issue JAN, 2019, Pages

  Karakike, Eleni ^a   Giamarellos Bourboulis, Evangelos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ferritin; Hemophagocytic lymphohistocytosis; Interferon gamma; Interleukins; Macrophage activation syndrome; Sepsis

Indexed keywords

AMINOTRANSFERASE; ANAKINRA; BIOLOGICAL MARKER; CD163 ANTIGEN; FERRITIN; FIBRINOGEN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; PATHOGEN ASSOCIATED MOLECULAR PATTERN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; CYTOKINE;

ADULT ONSET STILL DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; AUTOIMMUNE DISEASE; BLOOD CLOTTING DISORDER; CD8 LYMPHOCYTE COUNT; CYTOPENIA; DISSEMINATED INTRAVASCULAR CLOTTING; DNA SEQUENCE; ERYTHROPHAGOCYTOSIS; FEVER; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS; HEPATOBILIARY DISEASE; HEPATOSPLENOMEGALY; HISTIOCYTOSIS; HUMAN; HYPERFERRITINEMIA; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGENEMIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFLUENZA A (H1N1); MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MORTALITY; MULTIPLE ORGAN FAILURE; NATURAL KILLER T CELL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; GENETICS; HEMOPHAGOCYTIC SYNDROME; METABOLISM; SIGNAL TRANSDUCTION; SYMPTOM ASSESSMENT;

ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; SEPSIS; SIGNAL TRANSDUCTION; SYMPTOM ASSESSMENT;

EID: 85061605912     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.00055     Document Type: Review

References (38)

1. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. (2016) 12:259–68. doi: 10.1038/nrrheum.2015.179
2. Henter JI, Horne AC, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004 diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 48:124–31. doi: 10.1002/pbc.21039
3. Carcillo L, Carcillo JA. Secondary hemophagocytic lymphohistocytosis and severe sepsis/systemic inflammatory response/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. (2009) 10:387–92. doi: 10.1097/PCC.0b013e3181a1ae08
4. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. (2014) 66:2613–20. doi: 10.1002/art.38690
5. Barba T, Maucort-Boulch D, Iwaz J, Bohé J, Ninet J, Lega JC, et al. Hemophagocytic lymphohistiocytosis in intensive care unit. Medicine (2015) 94:e2318. doi: 10.1097/MD.0000000000002318
6. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. (2016) 172:412–9. doi: 10.1111/bjh.13837
7. Gormezano NW, Otsuzi CI, Barros DL, da Silva MA, Pereira RM, Campos LM, et al. Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients. Semin Arthritis Rheum. (2016) 45:706–10. doi: 10.1016/j.semarthrit.2015.10.015
8. Japtag N, Sharma M, Rajesh G, Rao PN, Anuradha S, Tandan M, et al. Hemophagocytic lymphohistiocytosis masquerading as acute liver failure: a single center experience. J Clin Exp Hepatol. (2017) 7:184–9. doi: 10.1016/j.jceh.2017.01.119
9. Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, et al. Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China. Clin Rheumatol. (2018) 37:93–100. doi: 10.1007/s10067-017-3625-6
10. Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. Clin Infect Dis. (2016) 213:1180–8. doi: 10.1093/infdis/jiv550
11. Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. (2014) 66:3486–95. doi: 10.1002/art.38793
12. Carter JS, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults, recent advances in pathophysiology, diagnosis and treatment. Rheumatology (2018) 58:5–17. doi: 10.1093/rheumatology/key006
13. Miettunen PV, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paedriatric rheumatic disease-associated macrophage activation syndrome with interleukin 1-inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (2011) 50:417–9. doi: 10.1093/rheumatology/keq218
14. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis /sepsis /multiple organ dysfunction / macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. (2014) 15:401–8. doi: 10.1097/PCC.0000000000000078
15. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. (2013) 4:289. doi: 10.3389/fimmu.2013.00289
16. Jordan MB, Hidlerman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood (2004) 104:735–43. doi: 10.1182/blood-2003-10-3413
17. Brisse E, Imbrechts M, Put K, Avau A, Mitera T, Berghmans N, et al. Mouse cytomegalovirus infection in BALB/c mice resembles virus-associated hemophagocytic lymphohistiocytosis and shows a pathogenesis distinct from primary hemophagocytic lymphohistiocytosis. J Immunol. (2016) 96:3124–34. doi: 10.4049/jimmunol.1501035
18. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. (2011) 121:2264–227. doi: 10.1172/JCI43157
19. Girard-Guyonvarc'h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood (2018) 131:1430–41. doi: 10.1182/blood-2017-06-789552
20. Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood (2018) 131:1442–55. doi: 10.1182/blood-2017-12-820852
21. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. (2013) 11:185. doi: 10.1186/1741-7015-11-185
22. Beer T, Vadakara J. Etiologies and short-term mortality in patients with ultraelevated serum ferritin. South Med J. (2015) 108:574–8. doi: 10.14423/SMJ.0000000000000339
23. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clin Exp Immunol. (2018) 191:220–8. doi: 10.1111/cei.13057
24. Sakamura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A. Soluble CD16, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine (2018) 110:459–65. doi: 10.1016/j.cyto.2018.05.017
25. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. sCD163 in AOSD, a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. (2014) 60:177–83. doi: 10.1007/s12026-014-8563-7
26. Signoff JK, Fitzerald JC, Teachey DT, Balamuth F, Weiss SL. Hypofibrinogenemia is associated with poor outcome and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome in pediatric severe sepsis. Pediatr Crit Care Med. (2018) 19:397–405. doi: 10.1097/PCC.0000000000001507
27. Ahn SS, Hwang SH, Jung SM, Lee SW, Park YB, Yun M, et al. The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome. Medicine (2017) 96:e7901. doi: 10.1097/MD.0000000000007901
28. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. (1997) 25:1115–24. doi: 10.1097/00003246-199707000-00010
29. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. (2016) 44:275–81. doi: 10.1097/CCM.0000000000001402
30. Kyriazopoulou K, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. (2017) 15:172. doi: 10.1186/s12916-017-0930-5
31. Karakike E, Adami ME, Lada M, Gkavogianni T, Koutelidakis IM, Bauer M, et al. Late peaks of HMGB1 and sepsis outcome: evidence for synergy with chronic inflammatory disorders. Shock (2018). doi: 10.1097/SHK.0000000000001265 [Epub ahead of print].
32. Palmblad K, Shierbeck H, Sundberg E, Horne AC, Harris HE, Henter JI, et al. High systemic levels of the cytokine inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med. (2014) 20:538–47. doi: 10.2119/molmed.2014.00183
33. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. (2017) 377:1119–31. doi: 10.1056/NEJMoa1707914
34. Carcillo JA, Sward K, Halstead ES, Telford R, Jimenez-Bacardi A, Shakoory B, et al. A systemic inflammation mortality risk assessment contingency table for severe sepsis. Pediatr Crit Care Med. (2017) 18:143–50. doi: 10.1097/PCC.0000000000001029
35. Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care (2012) 16:R52. doi: 10.1186/cc11256
36. Beutel G, Wiesner O, Eder M, Hafer C, Schneider AS, Kielstein JT, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care (2011) 15:R80. doi: 10.1186/cc10073
37. Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol. (2017) 37:638–43. doi: 10.1007/s10875-017-0439-x
38. Cui Y, Zhang YC, Kang YL, Ren YQ, Miao JJ, Wang F, et al. High-volume hemofiltration in critically ill patients with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a prospective study in the PICU. Pediatr Crit Care Med. (2016) 17:e437–43. doi: 10.1097/PCC.0000000000000896